KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Amortization of Deferred Charges (2016)

Charles River Laboratories International has reported Amortization of Deferred Charges over the past 7 years, most recently at $506000.0 for Q4 2016.

  • Quarterly results put Amortization of Deferred Charges at $506000.0 for Q4 2016, up 23.41% from a year ago — trailing twelve months through Dec 2016 was $2.8 million (up 18.95% YoY), and the annual figure for FY2016 was $2.8 million, up 18.95%.
  • Amortization of Deferred Charges for Q4 2016 was $506000.0 at Charles River Laboratories International, up from $34000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for CRL hit a ceiling of $4.6 million in Q1 2013 and a floor of $34000.0 in Q3 2016.
  • Median Amortization of Deferred Charges over the past 5 years was $436000.0 (2013), compared with a mean of $1.7 million.
  • Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 165.36% in 2015 and later tumbled 91.46% in 2016.
  • Charles River Laboratories International's Amortization of Deferred Charges stood at $4.5 million in 2012, then crashed by 90.26% to $437000.0 in 2013, then decreased by 2.29% to $427000.0 in 2014, then fell by 3.98% to $410000.0 in 2015, then rose by 23.41% to $506000.0 in 2016.
  • The last three reported values for Amortization of Deferred Charges were $506000.0 (Q4 2016), $34000.0 (Q3 2016), and $1.9 million (Q2 2016) per Business Quant data.